Row counts feel like ground truth. A database with 400,000 entries sounds comprehensive; one with 12,000 sounds thin. But a new analysis from Pure Global reveals that in the world of national medical device registries, those numbers can be profoundly — and dangerously — misleading. The research, covered by PR Newswire, examined 15 national public data files and found that divergent file structures and completeness gaps render raw record counts unreliable indicators of either regulatory coverage or market size. The implications hit compliance officers, market researchers, and device manufacturers squarely in the operating budget. The stakes are high in a sector where health market projections already run into the hundreds of billions.
The core problem is structural. Across the 15 databases surveyed, Pure Global found that what counts as a single row varies dramatically by country. Some registries record one row per device model. Others log one row per submission event, meaning a single product undergoing two regulatory updates appears as two distinct entries. Still others register one row per manufacturer location, so a multinational with five facilities logs five times in the dataset regardless of how many unique products it sells. The result is that a country with a smaller device market can appear, numerically, to have a larger registered footprint than a country with genuinely broader market penetration — purely because of how that nation’s regulatory body structured its export file.
The Completeness Problem Is Just as Damaging as the Structure Problem
File structure is only half the issue. Pure Global’s researchers also documented significant completeness gaps — fields that exist within a schema but are left blank in the majority of rows. In several of the 15 national files, critical identifiers such as device classification codes, manufacturer country of origin, and expiry or renewal dates were populated in fewer than half of all records. A compliance team running a market-entry check might see a device category flagged as registered, without realizing the registration record carries no classification code and therefore cannot be accurately matched against international product nomenclature standards like the Global Medical Device Nomenclature system.
That kind of silent gap is more treacherous than an obvious absence. When a field simply does not exist in a schema, analysts know to compensate. When a field exists but is sparsely populated, automated data pipelines often treat the sparse entries as representative — understating the problem and producing figures that look authoritative but reflect only a fraction of actual market conditions. For teams sizing addressable markets in regions across Southeast Asia, Latin America, or Eastern Europe, where several of the analyzed registries originate, this is not a theoretical risk. It produces concrete errors in revenue forecasts and regulatory submission strategies.
What Manufacturers and Market Analysts Need to Do Differently
Pure Global’s findings effectively argue for a methodological shift in how device registration data is consumed. Rather than treating row count as a proxy for market size or compliance coverage, the firm recommends that analysts first audit the structural logic of each national file before attempting any cross-country comparison. That means documenting what each row unit actually represents, mapping which fields are consistently populated versus systematically sparse, and normalizing records to a common unit — such as unique device identifier or product family — before aggregation. Without that normalization step, any multi-country dataset built from these 15 files will inherit and amplify the underlying distortions.
The analysis also carries a pointed message for regulatory intelligence platforms and data vendors that aggregate national registries into unified global databases. If the raw source files are structurally incompatible and incompleteness is not flagged at the field level, those aggregated products pass the distortions downstream to every client using them for compliance checks, competitive benchmarking, or pricing strategy. As device manufacturers push into more markets simultaneously — driven partly by the biologics medtech pipeline — the cost of relying on flawed registry data only compounds. Pure Global’s study does not offer a universal fix, but it does make one thing unmistakably clear: a bigger database number is not a better database number.
